Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial

Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial

<p><strong>Background: </strong>Determining a therapeutic window for maintaining antiretroviral drug concentrations within an appropriate range is required for identifying effective dosing regimens. The limits of this window are typically calculated using predictive models...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Schomaker, M, Denti, P, Bienczak, A, Burger, D, Díaz, I, Gibb, DM, Walker, AS, McIlleron, H
Natura:	Journal article
Lingua:	English
Pubblicazione:	Wiley 2024

Documenti analoghi

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
di: Bienczak, A, et al.
Pubblicazione: (2016)

Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children.
di: Bienczak, A, et al.
Pubblicazione: (2016)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource‐limited settings
di: Alemseged Abdissa, et al.
Pubblicazione: (2014-01-01)

Pharmacokinetics of antiretroviral drugs in infancy
di: Helen McIlleron, et al.
Pubblicazione: (2009-12-01)

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets
di: Bienczak, A, et al.
Pubblicazione: (2017)

Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.
di: Fillekes, Q, et al.
Pubblicazione: (2011)

The effect of diurnal variation, CYP2B6 genotype, and age on the pharmacokinetics of nevirapine in African Children
di: Bienczak, A, et al.
Pubblicazione: (2016)

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania
di: Selemani Saidi Sungi, et al.
Pubblicazione: (2018-10-01)

Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz
di: Larru B, et al.
Pubblicazione: (2014-05-01)

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
di: Mulenga, V, et al.
Pubblicazione: (2016)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
di: Kekitiinwa, A, et al.
Pubblicazione: (2017)

Getting drug doses right in children with tuberculosis (TB)
di: H. McIlleron
Pubblicazione: (2014-04-01)

‘Covering the tail’ after stopping efavirenz-based antiretroviral therapy
di: Gary Maartens
Pubblicazione: (2020-01-01)

Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
di: Musiime, V, et al.
Pubblicazione: (2014)

Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy
di: Innocent Lule Segamwenge, et al.
Pubblicazione: (2018-01-01)

Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy
di: Globahan Ajibola, et al.
Pubblicazione: (2020-01-01)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
di: Vandercam Bernard, et al.
Pubblicazione: (2010-05-01)

Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
di: Oudijk, J, et al.
Pubblicazione: (2012)

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy
di: Dorward, J, et al.
Pubblicazione: (2023)

A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis
di: Roeland E. Wasmann, et al.
Pubblicazione: (2023-04-01)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
di: Chang Huang, et al.
Pubblicazione: (2023-03-01)

Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy.
di: Jan Vesterbacka, et al.
Pubblicazione: (2013-01-01)

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis
di: Richard Court, et al.
Pubblicazione: (2021-04-01)

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission.
di: Patience Nyakato, et al.
Pubblicazione: (2020-01-01)

Combination of Antiretroviral Drugs Zidovudine and Efavirenz Impairs Tumor Growths in a Mouse Model of Cancer
di: Marcel A. Schneider, et al.
Pubblicazione: (2021-11-01)

Efavirenz in pregnancy
di: Polly Clayden, et al.
Pubblicazione: (2010-11-01)

Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
di: Lufina Tsirizani Galileya, et al.
Pubblicazione: (2023-11-01)

Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis
di: Lufina Tsirizani Galileya, et al.
Pubblicazione: (2023-11-01)

Estratégias utilizadas para o incremento da solubilidade do fármaco antiretroviral classe II: Efavirenz
di: Tarcyla Andrade Gomes, et al.
Pubblicazione: (2015-04-01)

Estratégias utilizadas para o incremento da solubilidade do fármaco antiretroviral classe II: Efavirenz
di: Tarcyla Andrade Gomes, et al.
Pubblicazione: (2015-10-01)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
di: Adelline Twimukye, et al.
Pubblicazione: (2021-11-01)

Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
di: Sanjeev Sinha, et al.
Pubblicazione: (2017-12-01)

Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans
di: Jenna Johnston, et al.
Pubblicazione: (2019-04-01)

Efavirenz-induced urolithiasis.
di: Wirth, G, et al.
Pubblicazione: (2006)

Efavirenz and neuropsychiatric effects
di: Mukesh Dheda
Pubblicazione: (2017-04-01)

Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study
di: Sinxadi Phumla Z, et al.
Pubblicazione: (2012-10-01)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
di: Gabriella Jomara da Silva, et al.
Pubblicazione: (2023-05-01)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
di: Rebecca Zash, MD, et al.
Pubblicazione: (2018-07-01)

Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil
di: T. Vanni, et al.
Pubblicazione: (2007-07-01)

Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe
di: Sandra Shawarira-Bote, et al.
Pubblicazione: (2019-08-01)